Project Grant R43AI186929
Award Date 7/16/26
Completion Date 6/30/27
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- Federal Project Grant Award Summary Protabit LLC received $304,602 in Project Grant funding from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective August 7, 2025, with completion targeted for July 31, 2026, supports the development of high-throughput engineering technologies for bispecific antibodies—therapeutic molecules that combine two different antigen-binding domains. The project...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Applied Biomedical Science Institute a Project Grant of $976,318 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 6, 2026, with completion targeted for March 31, 2031. The award funds research to elucidate the molecular mechanisms underlying ultralong complementarity-determining region H3 (CDR H3) antibodies produced by cattle. The Institute will...
- Federal Grant Award Summary Alpacure received a $300,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2026 through June 30, 2028. The award supports development of a single-domain antibody-based lateral flow assay for tuberculosis (TB) diagnosis. The project centers on optimizing variable heavy chain antibody fragments (VHH), also known as single-domain...
- Federal Project Grant Award Summary Award Details: Abvacc, Inc. received a $638,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was issued on August 22, 2025, with a completion date of July 31, 2030, and performance will be conducted in Rockville, Maryland. Products and Services: The grant funds development of an immunotherapeutic antibody cocktail for treating...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded La Jolla Institute for Immunology $923,708 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 1, 2026, for a five-year project concluding March 31, 2031. This Project Grant funds the development of a therapeutic monoclonal antibody (MAB) cocktail targeting New World Arenaviruses, including Machupo and Junin viruses, which cause hemorrhagic fever. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Broad Institute, Inc. a Project Grant totaling $481,250 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025, through July 31, 2027. The award supports the development of novel antimicrobial compounds based on induced proximity principles. The project involves the design and creation of chimeric molecules that combine binders of...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $279,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the La Jolla Institute for Immunology, effective April 1, 2026, through March 31, 2028. The grant funds detailed analysis of antibody repertoires from multiply-exposed individuals in the Democratic Republic of the Congo who demonstrate extraordinarily broad and strong humoral immune...
- Federal Grant Award Summary Biotherapeutics, Inc. received a $628,726 SBIR Phase 1 Project Grant awarded on August 13, 2025, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports the development of a novel, host-targeted, antibiotic-sparing oral therapeutic for the concurrent treatment of Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD). The innovative...
- Federal Project Grant Award Summary Tendel Therapies Inc. received a $999,991 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 13, 2025, with a completion date of July 31, 2028. The award supports the development and optimization of BSAB-98, a bispecific antibody (BSAB) therapeutic agent designed to deplete CCR5-expressing cells that form a critical component of the HIV...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Broad Institute, Inc. a Project Grant totaling $165,269 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research aimed at directing the evolution of common human antibody precursors into HIV-1 broadly neutralizing antibodies (BNAbs). The research, conducted in Cambridge, Massachusetts, focuses on addressing a critical gap in HIV vaccine development by identifying...